Background-Although appropriateness criteria for stress echocardiography have been developed to deliver high-quality care, the prognostic impact of these criteria remains undefined. Therefore, we sought to assess the prognostic implication of the American College of Cardiology/American Society of Echocardiography appropriateness criteria for pharmacological stress echo in a cohort of ambulatory patients. Methods and Results-The study population consisted of 1552 ambulatory patients who underwent pharmacological (752 dobutamine, 800 dipyridamole) stress echo for the evaluation of known (nϭ549) or suspected (nϭ1003) coronary artery disease at a single cardiology center. Patients were followed up for a median of 36 months. Indications were determined for consecutive studies by 2 reviewers and categorized as follows: 984 (63%) patients had appropriate, 145 (9%) uncertain, and 423 (27%) inappropriate indication for stress echo. Ischemia was present in 15% of patients with appropriate, 8% of those with uncertain, and 5% of those with inappropriate indication (PϽ0.0001). During follow-up, 146 events (89 deaths, 57 nonfatal infarctions) occurred. Annual event rate associated with appropriate, uncertain, and inappropriate study was 3.1%, 3.8%, and 1.3%, respectively. The abnormal test result in patients with appropriate, uncertain, and inappropriate study was associated with 5.0%, 5.6%, and 1.8% annual event rate, respectively, exerting an independent value only in the appropriate and uncertain subset.
I n US patients covered by Medicare, cardiac stress imaging has increased at an annual rate of 6% from 1993 to 2001. 1 During the same period, the total costs of noninvasive cardiac procedures nearly doubled in Canada. 2 The expansion of stress imaging is also expected in the United Kingdom, with a predicted 2-fold increase of pharmacological stress echocardiography and myocardial scintigraphy during the next decade. 3 Whether this rate of growth translates into clinical benefit to patients remains under debate. [3] [4] [5] [6] [7] Indeed, the increased utilization of diagnostic imaging has not been paralleled by a reduction in disease burden as the rate of hospitalization for myocardial infarction has remained nearly constant over time. 1 The growth of stress imaging raises concerns because of its economical impact [5] [6] [7] in the face of reduced available resources, the exposure of patients to potential risks of the study, 8 and the excessive delay in evaluation and management due to waiting for test performance and interpretation. 9 However, cost-effectiveness studies have demonstrated the pivotal role of noninvasive imaging for the selection of patients undergoing invasive and more expensive procedures. 10, 11 To reduce potential downstream costs and risks, appropriateness criteria were developed for several imaging techniques, including stress echocardiography. 12 The goal of these criteria is to identify "the right test, at the right time, for the right patients" 13 to deliver reasonable quality care. To the best of our knowledge, however, the prognostic impact of appropriateness criteria remains unsettled. Thus, the present study was aimed at assessing the relative prognostic contribution of the different levels of appropriateness criteria for pharmacological stress echo in a large sample of ambulatory patients.
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Methods Patients
The initial sample consisted of 1583 ambulatory patients who underwent pharmacologic stress echo at the Cardiology Division of Lucca Hospital, Italy, a tertiary care referral center, between January 2001 and December 2007. No patient had recent (Ͻ30 days) acute coronary syndrome, significant comorbidity reducing life expectancy to Ͻ1 year, or inadequate acoustic window. Of 1583 patients, 31 (2%) were lost to follow-up. The remaining 1552 patients (869 men, meanϮSD age 66Ϯ10 years) had complete follow-up information and formed the study group. Of them, 1003 (65%) had suspected coronary artery disease (CAD) and 549 (35%) had known CAD (ie, history of myocardial infarction and/or acute coronary syndromes, coronary revascularization, and/or angiographic evidence of Ͼ50% diameter coronary stenosis). The stressor used (752 dobutamine, 800 dipyridamole) was chosen on the basis of specific contraindications and physician's preferences. According to individual needs and physician's choices, 1387 (89%) patients were evaluated after antianginal drugs had been discontinued and 165 (11%) patients were evaluated during antianginal treatment (Table 1) . For patients (nϭ49) who repeated stress echo during follow-up, only the first examination was considered for the analysis. Diabetes mellitus, 14 arterial hypertension, 15 and hypercholesterolemia 16 were defined according to standard definitions. The study was approved by the institutional review board. All patients gave their written informed consent when they underwent pharmacological stress echo. When patients signed the written informed consent, they also authorized physicians to use their clinical data.
Indication Determination
The pharmacological stress echo database at Lucca Hospital is prospectively maintained to collect information about patient demographics, clinical history, outpatient or inpatient status, symptoms, ECG findings, result of prior exercise testing or the reasons for not having performed it, and resting and pharmacological stress echo findings. Two physicians (L.C., R.S.) unaware of follow-up data reviewed database information attributing the indication for each study according to the 87 clinical indications categorized into 9 tables addressed in the stress echo appropriateness criteria document. 12 In the case of disagreement, a third physician (R.B.) independently reviewed the data, and his judgment was binding for a final consensus indication. No patients had indication in document table 14 (risk assessment within 3 months of an acute coronary syndrome) or in document table 17 (stress study for hemodynamics). Because more than 1 indication could be established in an individual patient, in keeping with a previous experience, 17 the appropriateness criteria were applied according to the following hierarchical order: risk assessment: postrevascularization (appropriateness document table 7); risk assessment: perioperative evaluation for noncardiac surgery without active cardiac conditions (appropriateness document table 13); risk assessment after prior test results (appropriateness document table 12); detection of CAD or risk assessment: symptomatic or ischemic equivalent (appropriateness document table 9); assessment of viability/ischemia (appropriateness document table 16); detection of CAD or risk assessment: asymptomatic (without ischemic equivalent) (appropriateness document table 10); and detection of CAD or risk assessment: asymptomatic (without ischemic equivalent) in the patient sample with defined comorbidities (appropriateness document table 11). To determine the indication in appropriateness document table 9 (detection of CAD or risk assessment: symptomatic or ischemic equivalent), the pretest likelihood of CAD was calculated from age, sex, and symptoms. 18
Pharmacological Stress Echocardiography
Dobutamine (up to 40 g/kg per minute with coadministration of atropine up to 1 mg) and dipyridamole (up to 0.84 mg over 10 minutes with coadministration of atropine up to 1 mg, or up to 0.84 mg over 6 minutes) pharmacological stress echo tests were performed according to the well-established protocols. 19 Echocardiographic images were semiquantitatively assessed using a 17segment, 4-point scale model of the left ventricle. 20 A wall motion score index (WMSI) was derived by dividing the sum of individual segment scores by the number of interpretable segments. Ischemia was defined as stress-induced new and/or worsening of preexisting wall motion abnormality or biphasic response (ie, low-dose improvement followed by high-dose deterioration). Resting hypokinesis that remained unchanged or improved at peak stress was considered a negative test. Necrotic pattern was akinetic or dyskinetic myocardium with no thickening during stress. Resting hypokinesis was not considered scar. A test was considered abnormal in the case of inducible ischemia or necrotic pattern and normal in the case of no rest and stress wall motion abnormality.
Follow-Up Data
Outcome was determined from patient interview at the outpatient clinic, hospital chart reviews and telephone interviews with the patient, and his/her close relative or referring physician. Death and nonfatal myocardial infarction were registered as clinical events. Coronary revascularization (surgery or angioplasty) was also recorded. To avoid misclassification of the cause of death, 21 overall mortality was considered. Myocardial infarction was defined by typical symptoms, ECG, and cardiac enzyme change. Follow-up data were analyzed for the prediction of hard events (death or nonfatal myocardial infarction).
Statistical Analysis
Continuous variables are expressed as meanϮSD. Group means were compared using ANOVA, and frequencies were compared using the 2 test. The survival analysis was carried out by the Kaplan-Meier method and a competing risk analysis was performed. 22, 23 In this analysis, the appropriate estimate of the probability of failure is described by the so-called cumulative incidence and compared with the complement of a Kaplan-Meier estimate (1-KM). Multivariable analysis of survival was performed to identify significant prognostic factors. The multivariable analysis was done using the Cox proportional hazard regression model. The proportionality for each predictor was tested by Schoenfeld residuals. 24, 25 Hazard ratios (HR) with the corresponding 95% confidence interval (CI) were estimated. Statistical significance was set at PϽ0.05. STATA (Stata/SE release 10.0, StataCorp LP, College Station, TX) was used for analysis.
Results
Appropriateness of Testing
The appropriateness criteria document was applied in all cases, with 74% agreement between the 2 physicians in attributing the indication for testing. The agreement for each category of appropriateness is reported in Table 1 .
Of 1552 patients, 63% (nϭ984) had appropriate, 9% (nϭ145) had uncertain, and 27% (nϭ423) had inappropriate indication. Indication for stress echocardiography for detection of CAD/risk assessment: asymptomatic (without ischemic equivalent) and high global CAD risk (127 of the ACC document) was the most common uncertain indication, accounting for 52% (76/145) of uncertain studies, whereas indications on the evaluation of ischemic equivalent (nonacute) in patients with low test probability of CAD and ECG interpretable for CAD and able to exercise, asymptomatic patients postrevascularization Ͻ2 years, and The main clinical and echocardiographic findings for the 3 classes of appropriateness are illustrated in Table 2 . Inappropriate studies were more frequently ordered in younger patients and in those with prior angioplasty, whereas uncertain studies were more often indicated in men, diabetics, vasculopatics, and in patients with prior myocardial infarction or coronary surgery (Table 1) . Appropriate studies were more frequently ordered in women, patients with left bundlebranch block or paced rhythm, and in those with suspected CAD; in addition, they were more frequently conducted on anti-ischemic therapy ( Table 1 ).
Stress Echocardiographic Findings
No complications occurred during the test. Overall, 12% (nϭ182) of stress echocardiographic studies in the study group were found to have echocardiographic evidence of myocardial ischemia, with abnormal studies in 5% (nϭ23) of inappropriate, 8% (nϭ12) of uncertain, and 15% (nϭ147) of appropriate indication (PϽ0.0001). Abnormal results were evenly distributed in appropriate, uncertain, and inappropriate studies (Pϭ0.07) ( Table 1) .
Follow-Up Events
During a median follow-up of 36 months (1 st to 3 rd quartile; 19 -61 months), 146 patients had a cardiac event (89 deaths, 57 nonfatal infarctions): 104 (11%) with appropriate, 20 (14%) with uncertain, and 22 (5%) with inappropriate study (PϽ0.0001).
In addition, 226 patients underwent revascularization (55 surgery and 171 angioplasty) after a median of 68 days (interquartile range, 13-829) from the index stress echo. Revascularizations were more frequent in patients with ischemia than in those without ischemia at stress echo (49% versus 10%, PϽ0.0001). There were 171 (17%) revascularizations among patients with appropriate indication, 9 (6%) among patients with uncertain indication, and 
Survival Analysis
Annual event rate associated with appropriate, uncertain, and inappropriate study was 3.1%, 3.8%, and 1.3%, respectively. It was only 0.6% in subjects with inappropriate indication 124 (detection of CAD or risk assessment in asymptomatic [without ischemic equivalent] general patient sample with low global CAD risk). Individual and multivariable prognostic indicators are reported in Table 3 . Using the Cox proportional hazards model, age (PϽ0.0001), diabetes mellitus (PϽ0.0001), appropriate indication for testing (Pϭ0.001), peripheral arterial disease (Pϭ0.002), male sex (Pϭ0.002), abnormal test result (Pϭ0.005), prior angioplasty (Pϭ0.007), and uncertain indication for testing (Pϭ0.04) were associated with prognosis (Table 3) .
In the Cox model, analyzing the data separately in the 3 groups of appropriateness criteria, predictors of outcome were age (HR, 1.05; 95% CI, 1.03-1.08; PϽ0.0001), diabetes mellitus (HR, 1.97; 95% CI, 1.28 -3.04; Pϭ0.002), male sex (HR, 1.87; 95% CI, 1.22-2.87; Pϭ0.004), smoking habit (HR, 1.89; 95% CI, 1.78 -3.04; Pϭ0.008), abnormal test result (HR, 1.61; 95% CI, 1.07-2.42; Pϭ0.02), prior angioplasty (HR, 1.87; 95% CI, 1.11-3.13; Pϭ0.02), and peripheral arterial disease (HR, Revascularization is used as the event of interest to illustrate the differences in cumulative probability on estimates of "hard events" given by the 2 estimators (Kaplan-Meier estimate, 1-KM) and cumulative incidence. Lines are superimposable; the "cumulative incidence" estimator gives a similar estimate of 1-KM. Only for patients with appropriate indication for testing, the differences between the curves after 3 years become appreciable with an overestimation of 1-KM versus the cumulative incidence (PϽ0.02) after 5 years. It is therefore considered that the indicator 1-KM can be used in the description of our data. With the Cox method (maximum likelihood, proportional hazards models with covariates), appropriate and uncertain indication predicted similar event-rate (Pϭ0.63), higher than that of inappropriate indication (PϽ0.05 for both) (Figure 2 ). The abnormal test result in patients with appropriate, uncertain, and inappropriate study was associated with annual event rate of 5.0%, 5.6%, and 1.8%, respectively. Corresponding figures for the normal test were 2.2%, 2.3%, and 1.1%. Although annual event rate was greater in diabetics than in nondiabetics for each category of appropriateness, the inappropriate study identified subjects at lower risk in both patient groups (Figure 3 ).
Discussion
Our study demonstrates that the application of pharmacological stress echo appropriateness criteria 12 provides relevant prognostic information. Inappropriate indications for pharmacological stress echo are common, being documented in about 1 of 4 patients evaluated in an ambulatory setting, and is associated with better survival as compared with appropriate and uncertain indications. The study was designed to assess, on a large prospective data set, not only the applicability of appropriateness criteria but how the adherence to those criteria may influence outcome.
Comparison With Previous Studies
Consistent with previous reports describing 20% to 25% of inappropriate studies, 17,26 -28 we found 27% of our ambulatory patients to have inappropriately undergone stress echo, with 3 main clinical conditions encompassing 79% of inappropriate indications. These indications included symptomatic patients with low pretest probability of CAD having an interpretable ECG and the ability to exercise, asymptomatic patients who had undergone angioplasty less than 2 years before, and asymptomatic patients with low CAD risk. No study has addressed the prognostic value of appropriateness criteria in a high-volume outpatient clinic, evaluating patients with a wide range of disease severity from totally asymptomatic to revascularized subjects. Importantly, appropriateness criteria were predictive of both test result and survival. In fact, an appropriate study was associated with markedly higher frequency of test positivity and subsequent coronary revascularization and was an independent predictor of death or myocardial infarction. By contrast, inappropriate study identified patients at lower risk, particularly in asymptomatic patients with low CAD risk. Although an abnormal test result conferred independent prognostic stratification in the whole study sample, its prognostic value was significantly lower in the inappropriate study group, with a nearly 2.5 times lower yearly event-rate when compared with the appropriate indication group. Interestingly, an uncertain study yielded prognostic information comparable to an appropriate one in the entire study sample as well as in diabetic patients. However, the rate of test positivity was nearly 2 times lower in the uncertain than in the appropriate patient group. Although the majority of patients with an uncertain study were asymptomatic, they were more frequently diabetics and of male sex and with peripheral vasculopathy, which may explain, at least in part, their increased risk.
Clinical Implications
Of interest, and in keeping with previous experiences showing that 88% of all inappropriate myocardial perfusion imaging examinations were due to 4 most frequent inappropriate indications, 27 we found that 52% of all uncertain examinations were due to a single indication and that 79% of all inappropriate examinations were due to 3 indications. This highly repetitive pattern of inappropriateness points to a need for quality improvement and educational programs to achieve measurable improvements in results. In case of pharmacological stress echo, there is a gradient of risk moving from physical to pharmacological stress. In fact, major complications may occur in about 1 of 6000 cases during exercise, 1 of 1000 cases during dipyridamole, and 1 of 300 cases during dobutamine stress. 29 Our results show that an inappropriate stress echo provide a negligible prognostic information, due to the substantial low risk even in the case of abnormal result. These findings, showing the downstream effect of an inappropriate indication, reinforce the concept that unnecessary testing should be avoided in daily practice. Pharmacological stress echo is apparently of limited value in the subset of patients with uncertain test category that showed a higher incidence rate of previous myocardial infarction, hypertension and diabetes.
However, we cannot exclude that simplification and categorization of indications may offset the real value of pharmacological stress echo. It would be a tautology to state that uncertain results are uncertain, but a rate of misclassifications should be accounted for. No method is perfect, and our results demonstrate that the burden of proof should be linked to outcome studies. Some of our results are not surprising: inappropriate tests have a good outcome because most of the patients in this subgroup are either asymptomatic or with a low pretest probability of CAD; however, there were a number of adverse events in the inappropriate testing group that are not totally unexpected and serve as a reminder that application of a diagnostic algorithm must always include physician input into clinical decision-making. The adverse outcome in the appropriate subgroup was an expected result, due to the higher rate of positive test results and the higher prevalence of conditions predisposing to adverse outcomes independent of test results.
Study Limitations
Several limitations should be acknowledged for the present study. This is a prospective data bank, but the application of appropriateness criteria was retrospective. In fact, we reclassified all the historic data set on the basis of the appropriateness criteria. However, the data were acquired in a prospective fashion and entered the databank at the time of initial assessment. It is likely that in a subset of tests, the data available were not complete enough to optimally identify the corresponding clinical scenario and that the lack of critical information in the data bank may have increased the number of inappropriate tests. Therefore, there is a risk of overestimating the number of uncertain and inappropriate tests; however, the rate of these subclasses in our study is not different from previously published reports. 28 The results of the tests, available to the referring physicians, might have influenced the clinical treatment of the patients, especially regarding coronary revascularization, but this might have only lowered the prognostic power of the test, as patients were censored at the time of the procedure. Moreover, this may have introduced a bias, particularly in the uncertain group of subjects, in whom the ambiguity of the indication was mirrored by a higher level of clinical risk, influencing outcome. Unlike 2 previous studies 17,28 that adopted 2008 appropriateness criteria for stress echo 30 reporting 12% and 19% of patients not classified, we addressed all the indications ordered in our clinical practice. The reduction of areas of uncertainties in the updated document, 12 differences in clinical scenarios, clinical information collected at the time of testing, and personnel reviewing the data may account for this, at least in part. No filter at the time of clinical request was made, and again this may have significantly increased the number of uncertain indications. The present results were obtained in a tertiary care referral center and may not be extended to a primary care environment. Several factors may influence the ordering of an inappropriate test such as financial incentives, lack of physician confidence in clinical assessment skills, patient insistence, and lack of a filtering order system. The appropriateness criteria were applied only to pharmacological stress testing and both dipyridamole and dobutamine were lumped together: they exert the same prognostic power when state of the art protocols are used as recommended by the European Association of Echocardiography. 19 We accepted published guidelines as the only possible gold standard against which to assess appropriateness. The approach to defining appropriateness from guidelines is simple but is limited because this process does not allow the evaluation of nuances according to the situation of the patient. In addition, most of the guidelines and society recommendations are based on level of evidence C, which is the consensus of the monitoring committee in the absence of a firm evidence base. 31
Conclusion
Appropriateness is the new imperative 5 in contemporary medicine and is the fruit of a paradigm shift in health care, which relates the boost of cardiac imaging to higher costs, more risks, and no real clinical impact. Our results confirm the high number of inappropriate tests in a high volume laboratory and provide insights into the prognostic performance of pharmacological stress echo appropriateness criteria on long-term follow-up. Appropriate and inappropriate studies identify patients at high and low risk, respectively, for hard cardiac events. More prospective data are needed to assess the real impact of appropriateness criteria on different patient samples undergoing pharmacological stress echo.
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CLINICAL PERSPECTIVE
Appropriate use of imaging is the new imperative of contemporary medicine. In the words of the American College of Cardiology Foundation committee, "appropriate echocardiograms are those that are likely to contribute to improving patients' clinical outcomes, and importantly, inappropriate use of echocardiography may be potentially harmful to patients and generate unwarranted costs to the healthcare system." Hence, these criteria stem from a real practical need to reduce costs and avoid abuse and misuse of noninvasive imaging technologies. Even though appropriateness criteria are highly cited and referred to, the real impact of these documents is yet to come. These results attempt to shed light on the prognostic impact of the criteria and tell us that appropriate tests identify patients at higher risk of events during follow-up, whereas inappropriate studies, performed on low-risk patients, identify a subset at very low risk.
